ERBB2 and neoplasm: When animals that had rejected the initial tumor and the first rechallenge with GL261/ErbB2 were injected once again with GL261/ErbB2 cells but this time after depletion of CD4+ and CD8+ T cells, tumors formed in a large proportion of the mice.